Researchers are excited about the medication , a groundbreaking dual agonist showing remarkable data in initial trials for weight reduction . It acts by impacting two pathways : GLP-1 and GIP, which , https://agnesouda751725.blogdun.com/41458431/the-new-hope-for-size-management